Keyword Analysis & Research: adar1
Keyword Research: People who searched adar1 also searched
Search Results related to adar1 on Search Engine
-
ADAR1: a mast regulator of aging and immunity - Nature
https://www.nature.com/articles/s41392-022-01276-5
WebJan 4, 2023 · Recently, Nature and Nature Cell Biology published five papers on the function and molecular mechanism of ADAR1 (adenosine deaminases acting on RNA) in aging, cancer, and autoimmune diseases. 1,...
DA: 14 PA: 42 MOZ Rank: 50
-
ADAR1 RNA editing enzyme regulates R-loop formation and genome ... - Nature
https://www.nature.com/articles/s41467-021-21921-x
WebMar 12, 2021 · ADAR1 is involved in adenosine-to-inosine RNA editing. The cytoplasmic ADAR1p150 edits 3’UTR double-stranded RNAs and thereby suppresses induction of interferons.
DA: 29 PA: 16 MOZ Rank: 3
-
Loss of ADAR1 in tumours overcomes resistance to immune ... - Nature
https://www.nature.com/articles/s41586-018-0768-9
WebDec 17, 2018 · Here we show that loss of function of the RNA-editing enzyme ADAR1 in tumour cells profoundly sensitizes tumours to immunotherapy and overcomes resistance to checkpoint blockade.
DA: 61 PA: 21 MOZ Rank: 61
-
ADAR1 is a new target of METTL3 and plays a pro-oncogenic role …
https://genomebiology.biomedcentral.com/articles/10.1186/s13059-021-02271-9
WebJan 28, 2021 · We show that ADAR1 plays a cancer-promoting role independently of its deaminase activity by binding CDK2 mRNA, underlining the importance of ADARs as essential RNA-binding proteins for cell homeostasis as well as cancer progression. Additionally, we show that ADAR1 knockdown is sufficient to strongly inhibit glioblastoma growth in vivo.
DA: 49 PA: 45 MOZ Rank: 45
-
ADAR1: A New Target for Immuno-oncology Therapy - Cell Press
https://www.cell.com/molecular-cell/fulltext/S1097-2765(19)30132-7
WebMar 7, 2019 · show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target. Main Text Adenosine-to-Inosine (A-to-I) RNA editing is catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes that bind and edit double-stranded …
DA: 46 PA: 65 MOZ Rank: 45
-
ADAR gene: MedlinePlus Genetics
https://medlineplus.gov/genetics/gene/adar/
WebThe ADAR1 protein is involved in the control of the innate immune response, which is the immune system's early response to foreign invaders (pathogens). The adenosine-to-inosine editing performed by ADAR1 is thought to change certain areas of the body's own RNA that the immune system might interpret as belonging to a virus that should be attacked.
DA: 50 PA: 65 MOZ Rank: 31
-
ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669771/
WebJul 25, 2019 · Recent advances indicate that the adenosine deaminase ADAR1 through RNA editing is involved in dampening the canonical antiviral RIG-I-like receptor-, PKR-, and OAS-RNAse L pathways to prevent autoimmunity. However, this inhibitory effect must be overcome during viral infections.
DA: 92 PA: 66 MOZ Rank: 57
-
The role of RNA editing enzyme ADAR1 in human disease
https://pubmed.ncbi.nlm.nih.gov/34105255/
WebADAR1-mediated editing of endogenous coding and noncoding RNA as well as ADAR1 editing-independent interactions with DICER can also have oncogenic or tumor suppressive effects that affect tumor proliferation, invasion, and response to immunotherapy.
DA: 95 PA: 26 MOZ Rank: 93
-
Emerging role of the RNA-editing enzyme ADAR1 in stem cell fate …
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00503-7
WebJun 6, 2023 · ADAR1, a specific adenosine deaminase, binds to dsRNA and converts adenosine (A) to inosine (I) after RNA transcription, which is known as A-to-I editing [ 33 ]. It contains three isoforms, p150, p110 and p80 [ 34, 35 ]. P150 has been reported to be involved in the regulation of type I interferon signaling [ 36 ].
DA: 43 PA: 37 MOZ Rank: 9
-
ADAR1: A New Target for Immuno-oncology Therapy - PubMed
https://pubmed.ncbi.nlm.nih.gov/30849393/
WebMar 7, 2019 · Substances. Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.
DA: 64 PA: 71 MOZ Rank: 4